News for Acer Therapeutics Inc. (ACER)

Zevra Therapeutics Inc. (ZVRA), which emerged as a commercial-stage company in 2024, is continuing its transformation into a patient-focused leader in rare disease therapeutics.

Timothy Kieffer, Ph.D., appointed Chief Scientific Officer Danny Villeneuve appointed Chief Commercial Officer Terrie Kellmeyer, Ph.D., appointed Senior Vice Pr

**media[630787]**

Relief Therapeutics Secures up to $11 Million from Royalty Sales

Strengthening Operational Efficiency and Execution towards Sustainable Accessibility for Diverse Populations within Global Healthcare Systems...

Launch of OLPRUVA® underway Topline results from KP1077 phase 2 study demonstrate clinically meaningful benefits for key IH symptoms Q4 2023 net revenue...

WALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...

NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the securities of Genesis Growth Tech Acquisition...

Acer Therapeutics Inc. dropped from S&P TMI Index...

Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results....

NEW YORK, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential...

NEW YORK, Oct. 08, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential...

NEW YORK, Sept. 18, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...

/PRNewswire/ -- The urea cycle disorder treatment market size is expected to grow by USD 235.5 million from 2022 to 2027. In addition, the momentum of the...

BALA CYNWYD, Pa., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to...

Relief Therapeutics Holding AG announced it has entered into a new exclusive definitive licensing agreement with Acer Therapeutics Inc. for the development and commercialization of OLPRUVA? for the...

U.S. stocks traded mixed toward the end of trading, with the Dow Jones trading slightly higher on Tuesday.

U.S. stocks traded mixed midway through trading, with the Dow Jones gaining around 100 points on Tuesday.

By Mary de Wet Acer Therapeutics Inc. has received approval from the Food and Drug Administration for Olpruva, the first of four drugs the company was investigating. The drug, also known... | December 23, 2022